Genetic stratification of motor and QoL outcomes in Parkinson's disease in the EARLYSTIM study.

[1]  R. Krüger,et al.  GBA-associated PD: chances and obstacles for targeted treatment strategies , 2022, Journal of Neural Transmission.

[2]  Alicia R. Martin,et al.  Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps , 2021, Nature Medicine.

[3]  G. Deuschl,et al.  Changing Gears – DBS For Dopaminergic Desensitization in Parkinson's Disease? , 2021, Annals of neurology.

[4]  M. Nalls,et al.  Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson’s Disease , 2020, medRxiv.

[5]  J. Aasly.  Long-Term Outcomes of Genetic Parkinson’s Disease , 2020, Journal of movement disorders.

[6]  G. Deuschl,et al.  Comparing two randomized deep brain stimulation trials for Parkinson's disease. , 2020, Journal of neurosurgery.

[7]  Sonja W. Scholz,et al.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[8]  P. O’Reilly,et al.  PRSice-2: Polygenic Risk Score software for biobank-scale data , 2019, GigaScience.

[9]  A. Fasano,et al.  Deep Brain Stimulation in Patients With Mutations in Parkinson's Disease–Related Genes: A Systematic Review , 2019, Movement disorders clinical practice.

[10]  G. Deuschl,et al.  Quality of life predicts outcome of deep brain stimulation in early Parkinson disease , 2019, Neurology.

[11]  M. Contarino,et al.  Association of Subthalamic Deep Brain Stimulation With Motor, Functional, and Pharmacologic Outcomes in Patients With Monogenic Parkinson Disease , 2019, JAMA network open.

[12]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[13]  M. Nalls,et al.  Multimodal neuroimaging and behavioral assessment of α-synuclein polymorphism rs356219 in older adults , 2018, Neurobiology of Aging.

[14]  Sonja W. Scholz,et al.  NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases , 2017, Neurobiology of Aging.

[15]  C. Mariani,et al.  Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.

[16]  Alan M. Kwong,et al.  Next-generation genotype imputation service and methods , 2016, Nature Genetics.

[17]  M. Toft,et al.  A cumulative genetic risk score predicts progression in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.

[18]  I. Toni,et al.  Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers , 2015, Neurology.

[19]  N. Brüggemann,et al.  Parkin Type of Early-Onset Parkinson Disease , 2013 .

[20]  G. Deuschl,et al.  Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.

[21]  C. Plewnia,et al.  Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinson’s disease , 2012, Journal of Neurology.

[22]  Keith Wheatley,et al.  Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial , 2010, The Lancet Neurology.

[23]  Jeffrey N. Browndyke,et al.  Genetic Regulation of α-Synuclein mRNA Expression in Various Human Brain Tissues , 2009, PloS one.

[24]  A. Brice,et al.  Parkinson's disease: from monogenic forms to genetic susceptibility factors. , 2009, Human molecular genetics.

[25]  D. Berg,et al.  Genetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  G. Deuschl,et al.  A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.

[27]  E. Montgomery.  Predictors of effective bilateral subthalamic nucleus stimulation for PD , 2003, Neurology.